BRCA1
BRCA1 (BRCA1 DNA repair associated, also known as RNF53, BRCC1, PPP1R53 and FANCS) is a nuclear E3 ubiquitin-protein ligase and tumour suppressor. It supports DNA repair, cell cycle checkpoint control and transcriptional regulation to maintain genomic stability. Browse Assay Genie's current range of BRCA1 research reagents below, or read on for the biology behind the target.
BRCA1 is an E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. The BRCA1-BARD1 heterodimer coordinates DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. BRCA1 is required for appropriate cell cycle arrests after ionizing irradiation in both S-phase and G2, and for targeting FANCD2 to sites of DNA damage. It also regulates centrosomal microtubule nucleation and acts as a transcriptional activator.
BRCA1 contributes to homologous recombination repair through its direct interaction with PALB2, and it fine-tunes recombinational repair partly by modulating the PALB2-dependent loading of the BRCA2-RAD51 repair machinery at DNA breaks. As part of the BRCA1-RBBP8 complex, it regulates CHEK1 activation and controls G2/M checkpoints after DNA damage through ubiquitination of RBBP8. It also inhibits lipid synthesis by binding inactive phosphorylated ACACA and preventing its dephosphorylation. The protein is found in the nucleus, on chromosomes and in the cytoplasm, and alternative splicing helps determine its subcellular localisation and function.
The BRCA1 gene encodes a nuclear phosphoprotein that combines with other tumour suppressors, DNA damage sensors and signal transducers in the BRCA1-associated genome surveillance complex (BASC). It associates with RNA polymerase II and, through its C-terminal domain, with histone deacetylase complexes, linking it to transcription, double-strand break repair and recombination. Mutations in the BRCA1 gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. HGNC lists it among the RING finger proteins and the Fanconi anaemia complementation groups, and mouse and rat orthologs are both named Brca1.
BRCA1 facilitates cellular responses to DNA damage and is needed for cell cycle arrest after ionizing irradiation and for FANCD2 targeting to damage sites.
Through PALB2, BRCA1 influences loading of the BRCA2-RAD51 machinery at DNA breaks, making it central to studies of recombinational repair.
Mutations in BRCA1 account for roughly 40% of inherited breast cancers and over 80% of inherited breast and ovarian cancers.
As an E3 ligase forming Lys-6-linked polyubiquitin chains, BRCA1 with BARD1 links ubiquitination to genome stability and transcriptional regulation.
BRCA1 is an E3 ubiquitin-protein ligase that forms Lys-6-linked polyubiquitin chains and has a central role in DNA repair. With BARD1 it coordinates DNA damage repair, ubiquitination and transcription, and it contributes to cell cycle checkpoints and homologous recombination repair.
The HGNC name is BRCA1 DNA repair associated, and UniProt calls the protein breast cancer type 1 susceptibility protein. Aliases and previous symbols include RNF53, BRCC1, PPP1R53 and FANCS. Earlier names were breast cancer 1, early onset, and breast cancer 1. Many alternatively spliced transcript variants have been described.
Yes. Mutations in the BRCA1 gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Mouse and rat orthologs are both called Brca1; check the datasheet of any product for its validated reactivity.
BRCA2, the partner in BRCA2-RAD51 loading at DNA breaks, and other targets involved in homologous recombination repair.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P38398; product specifications from Assay Genie datasheets.